Home Forums Melanoma Diagnosis: Stage IV High risk of recurrence target CD20 – rituximab

  • This topic is empty.
Viewing 2 posts - 1 through 2 (of 2 total)
  • Author
  • #20687

    I think this may be one for Catherine to ask one of the scientific board members.

    I read an abstract Molecular Therapy,(21 February 2012) doi:101038/mt.2012.27

    Rituximab was given to nine patients at high risk melanoma recurrence( they were stage IV but rendered disease free via surgery chemo and or radiation). A small group of patients had a good outocome 6 /9 alive 5 recurrence free 2 years after the therapy ended.

    For those ineligible for any trials would this be something we might wish to consider. Would having had ipilimumab 2 years ago be a problem- would ipilimumab make this more risky ?

    Catherine Poole

    Gosh, I don’t like what I read about this therapy: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607038.html

    But is there a trial with this going on now? Sounds like very small numbers.

Viewing 2 posts - 1 through 2 (of 2 total)
  • The forum ‘Melanoma Diagnosis: Stage IV’ is closed to new topics and replies.